Johnson & Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel. Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs.
Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. Shares of ISIS fell by 0.28% or $-0.17/share to $61.57. In the past year, the shares have traded as low as $22.25 and as high as $67.12. On average, 2623680 shares of ISIS exchange hands on a given day and today's volume is recorded at 2086020.
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Shares of JNJ fell by 0.05% or $-0.05/share to $104.52. In the past year, the shares have traded as low as $86.09 and as high as $109.49. On average, 8246330 shares of JNJ exchange hands on a given day and today's volume is recorded at 5756961.
Source
